Navigation Links
Keppra XR(TM) Extended-Release Tablets Filed with the FDA
Date:1/16/2008

older with juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy. Keppra(R) injection is indicated as adjunctive therapy in the treatment of myoclonic seizures in juvenile myoclonic epilepsy and partial onset seizures in adults with epilepsy. Keppra(R) injection is an alternative for patients when oral administration is temporarily not feasible.

Keppra(R) tablets and oral solution are associated with the occurrence of central nervous system adverse events including somnolence and fatigue, behavioral abnormalities, as well as hematological abnormalities. In adults experiencing partial onset seizures, Keppra(R) is also associated with coordination difficulties. In adults experiencing partial onset seizures, the most common adverse events associated with Keppra(R) in combination with other AEDs were somnolence, asthenia, infection and dizziness. In pediatric patients 4-16 years of age experiencing partial onset seizures, the most common adverse events associated with Keppra(R) in combination with other AEDs were somnolence, accidental injury, hostility, nervousness and asthenia. In patients 12 years of age and older with juvenile myoclonic epilepsy, the most common adverse events associated with Keppra(R) in combination with other AEDs were somnolence, neck pain, and pharyngitis. In patients 6 years of age and older with idiopathic generalized epilepsy, the most common adverse event associated with Keppra(R) in combination with other AEDs was nasopharyngitis.

The adverse events that result from Keppra(R) injection use for myoclonic seizures in juvenile myoclonic epilepsy and partial onset seizures in adults include all of those associated with Keppra(R) tablets and oral solution.

U.S. prescribing information is available at http://www.keppra.com or by calling 1-866-822-0068.

Furthe
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets
2. SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
3. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
4. New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
5. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
6. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Tobramycin Market, 2010-2019" ... traditional antibiotic whose eye drop and ointment are the ... infection or inflammation caused by eye infection. Currently, dozens ... able to produce tobramycin, among which the Top 5 ...
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "Investigation Report ... their offering. Developed by Pharmacia & ... receptor agonist which effectively reduces intraocular pressure. As ... latanoprost (under the trade name of Xalatan) entered ...
(Date:8/28/2015)...  Perrigo Company plc ("Perrigo") (NYSE: PRGO ; ... of leading OTC brands from GSK in an all ... a clear demonstration of Perrigo,s unique ability to maximize ... spanning 36 countries.  Perrigo Chairman, President ... are excited to complete this transaction, which clearly demonstrates ...
Breaking Medicine Technology:Investigation Report on China's Tobramycin Market, 2015-2019 2China Latanoprost Market Investigation Report 2015-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4
... FRANCISCO, Nov. 13 Quantros, a leading software ... that it has partnered with Det Norske Veritas ... by the Centers for Medicare and Medicaid Services ... now integrate that company,s accreditation standards into the ...
... Nov. 13 /PRNewswire/ Millar Instruments, Inc., developer and ... (P-V) systems, and Transonic Systems, Inc., global leader ... measurement devices, today announce a new distribution partnership. ... giants in the field of physiological measurements, Transonic ...
Cached Medicine Technology:Quantros Announces Partnership With Hospital Accreditation Agency DNV 2Millar Instruments and Transonic Systems, Suppliers of Gold Standard Pressure and Flow Products, Enter Into Mutual Distribution Agreement 2
(Date:8/28/2015)... ... August 28, 2015 , ... The Quatela Center for Plastic Surgery ... first and only nonsurgical product approved by the Food and Drug Administration to eliminate ... and Dr. William Koenig are among the premier cosmetic surgeons in Rochester ...
(Date:8/28/2015)... IL (PRWEB) , ... August 28, 2015 , ... Mendon, ... evening of good music and good people, all for a good cause. In its ... 30th, 2015, sponsored once more by Best Drug Rehabilitation. The “Mission” of “Music With ...
(Date:8/28/2015)... ... August 28, 2015 , ... Healthpointe clinics throughout Southern ... sea diving. The act of recreational diving exposes the body to extreme ... is vital that all recreational and professional divers undergo regular comprehensive scuba physicals. ...
(Date:8/28/2015)... ... August 28, 2015 , ... The newest therapy to receive ... for general use any time soon, according to educational website Surviving Mesothelioma. Click ... received orphan drug designation for mesothelioma last week from the FDA, will now head ...
(Date:8/28/2015)... ... August 28, 2015 , ... United ... to welcome TJS Insurance Group as its newest Partner Firm. Founded in 1924 ... and keeps them focused on their goals. Within the past 10 years, TJS ...
Breaking Medicine News(10 mins):Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2Health News:Healthpointe Now Offering Scuba Physicals 2Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 3
... Philadelphia, 11 December 2008 An implantable hemodynamic monitor ... large subgroup of patients with heart failurethose with diastolic ... Journal of Cardiac Failure ( http://www.onlinejcf.com/ ), ... M.D., of Medical University of South Carolina, Charleston, the ...
... a goal of all European health care systems. Despite ... still very much at risk during the perinatal period, ... The European Perinatal Health Report released by the EURO-PERISTAT ... to date and takes a new approach to health ...
... year from infectious diseases, despite the availability of ... penicillin to treat bacterial infections, along with the ... such as polio and smallpox, achieved great reductions ... spectacular advances in medical imaging combined with mathematical ...
... in Multiple States, Lockheed Martin Presents Example of How ... , , NASHVILLE, Tenn., ... provider of managed care market intelligence, finds that with ... with carriers across the country to provide benefits to ...
... Dean bring lessons learned from California reform debate to ... , WASHINGTON, Dec. 11 Two ... Catholic Healthcare West (CHW) President / CEO Lloyd Dean ... Bodaken -- are founding members of Health CEOs for ...
... Wound Management,Technologies, Inc., (OTC Bulletin Board: WNDM), ... of BioPharma Management Technologies, Inc.,a company that has ... "While we have been focusing this year ... also have been working,to expand our current product ...
Cached Medicine News:Health News:Implantable monitor may help in managing diastolic heart failure 2Health News:Comparable data on maternal and infant in Europe available for the first time 2Health News:Comparable data on maternal and infant in Europe available for the first time 3Health News:Mathematical models of adaptive immunity 2Health News:Mathematical models of adaptive immunity 3Health News:Employer Vantage From HealthLeaders-InterStudy Provides a Snapshot of Both Self- and Fully-Insured Health Benefits to Help Pharmaceutical and Diagnostic Manufacturers Identify Business Opportunities 2Health News:Employer Vantage From HealthLeaders-InterStudy Provides a Snapshot of Both Self- and Fully-Insured Health Benefits to Help Pharmaceutical and Diagnostic Manufacturers Identify Business Opportunities 3Health News:California Health Industry Leaders Help Launch National CEO Coalition for Health Reform 2Health News:California Health Industry Leaders Help Launch National CEO Coalition for Health Reform 3Health News:California Health Industry Leaders Help Launch National CEO Coalition for Health Reform 4Health News:California Health Industry Leaders Help Launch National CEO Coalition for Health Reform 5Health News:Wound Management Technologies, Inc. Announces Negotiations to Acquire BioPharma Management Technologies, Inc. 2Health News:Wound Management Technologies, Inc. Announces Negotiations to Acquire BioPharma Management Technologies, Inc. 3
... This therapeutic system ... the patient in mind. ... surgery and ongoing therapy, ... low-risk and effective therapy. ...
All the power and performance of the STS - T but now available with a stand-alone 9" II C-Arm...
... not only one of the most modern lithotripters ... Apart from being designed for the treatment of ... tract, the MODULITH SLX can also be employed ... is equally suitable for the treatment of gallstones ...
... STORZ MEDICAL is the result of many ... of kidney stone lithotripsy and the successful ... met by orthopaedic apparatus for extracorporeal shock ... The MINILITH SL1 is characterized by its ...
Medicine Products: